Effectiveness of Novel versus Conventional Phosphate Binder in Managing Hyperphosphatemia in Chronic Kidney Disease

A BSTRACT Objective: This study evaluates and compares the effectiveness of novel phosphate binders (PBs) with conventional PBs in lowering blood phosphorus concentration in individuals with chronic kidney disease (CKD) who have hyperphosphatemia. The objective is to determine whether the novel PB demonstrates superior efficacy in managing elevated phosphate levels compared to traditional binders. In addition, the study seeks to evaluate and compare the safety profiles of both treatment options and provide evidence to guide optimal therapeutic decisions for phosphate management in CKD patients. Methodology: This study has been conducted at Dhiraj Hospital, Vadodara, Gujarat. The study involved 46 patients as per the inclusion and exclusion criteria for CKD associated with hyperphosphatemia. Participants were treated with either the novel PB or a conventional one, with phosphate levels monitored before and after treatment. Data were analyzed using Excel, and accordingly, result is concluded. Results: The total number of individuals included in our study is 46, out of which 16 received the novel PB, resulting in a 25.99% improvement. In contrast, 24 patients undergoing conventional PBs have shown 15.86% improvement, and remaining 6 patients who received combination PBs therapy showed 23.66% improvement in managing phosphate levels reduction. Conclusion: The novel PBs demonstrated greater efficacy in lowering phosphate levels compared to conventional and combinational PB therapy, with a 25.99% average improvement. It also reduced pill burden and had manageable side effects. These findings suggest sucro-bind is more effective for treating hyperphosphatemia in CKD.